Aspira Women’s Health (NASDAQ:AWH) Research Coverage Started at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a research report issued on Friday. The brokerage set a “hold” rating on the stock.

Separately, Cantor Fitzgerald reissued a “neutral” rating and issued a $3.30 price target on shares of Aspira Women’s Health in a research report on Wednesday, April 10th.

Aspira Women’s Health Price Performance

NASDAQ:AWH opened at $2.04 on Friday. The firm has a market capitalization of $25.40 million, a price-to-earnings ratio of -1.41 and a beta of 1.50. Aspira Women’s Health has a 1 year low of $1.74 and a 1 year high of $6.75. The business has a 50 day simple moving average of $2.80 and a 200-day simple moving average of $3.55.

Aspira Women’s Health (NASDAQ:AWH) last issued its quarterly earnings results on Tuesday, May 21st. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.03). The business had revenue of $2.15 million for the quarter, compared to the consensus estimate of $2.10 million. Aspira Women’s Health had a negative return on equity of 1,099.32% and a negative net margin of 163.95%. During the same period in the prior year, the business posted ($10.94) earnings per share. As a group, analysts expect that Aspira Women’s Health will post -1.3 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aspira Women’s Health

A number of large investors have recently bought and sold shares of AWH. Northeast Financial Consultants Inc purchased a new position in Aspira Women’s Health in the third quarter worth approximately $126,000. Quantum Private Wealth LLC boosted its position in shares of Aspira Women’s Health by 76.8% during the fourth quarter. Quantum Private Wealth LLC now owns 50,156 shares of the company’s stock worth $205,000 after buying an additional 21,788 shares during the period. Finally, B. Riley Wealth Advisors Inc. boosted its position in shares of Aspira Women’s Health by 39.0% during the third quarter. B. Riley Wealth Advisors Inc. now owns 125,374 shares of the company’s stock worth $672,000 after buying an additional 35,177 shares during the period. Institutional investors and hedge funds own 12.19% of the company’s stock.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.